Description: A hybrid vaccine adjuvant is a formulation that combines different types of adjuvants to enhance the immune response generated by a vaccine. Adjuvants are substances added to vaccines to improve their efficacy by stimulating the immune system and prolonging the duration of the immune response. The combination of adjuvants can optimize the activation of specific immune cells, such as T and B lymphocytes, resulting in a more robust and long-lasting response against pathogens. These hybrids may include components of both natural and synthetic origin, allowing for customization based on the type of disease being targeted for prevention. Research into hybrid adjuvants has increased in recent decades, driven by the need to develop more effective vaccines against infectious diseases and, more recently, against non-communicable diseases. Their relevance lies in the ability to enhance the immunogenicity of vaccines, which is crucial in the context of epidemic outbreaks and pandemics, where a rapid and effective response is required. In summary, hybrid adjuvants represent a significant innovation in vaccine formulation, offering a more versatile and effective approach to disease prevention.
